title: Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2.
abstract: OBJECTIVE
  To explore the possible mechanisms of curcumin in rat colitis induced by trinitrobenzene sulfonic (TNBS) acid.
  
  
  METHODS
  Rats with TNBS acid-induced colitis were treated with curcumin (30 mg/kg or 60 mg/kg per day ip). Changes of body weight and histological scores as well as survival rate were evaluated. Leukocyte infiltration was detected by myeloperoxidase (MPO) activity assay. The expression of cyclooxygenase-2 (COX-2) was detected by RT-PCR and Western blot. Inflammation cytokines were determined by RT-PCR. Local concentration of prostaglandin E(2) (PGE(2)) in colon mucosa was determined by ELISA.
  
  
  RESULTS
  Curcumin improved survival rate and histological image, decreased the macroscopic scores and MPO activity. Also curcumin reduced the expression of COX-2 and inflammation cytokines. In addition, treatment with curcumin increased the PGE(2) level.
  
  
  CONCLUSIONS
  Curcumin has therapeutic effects on TNBS acid-induced colitis, the mechanisms seem to be related to COX-2 inhibition and PGE(2) improvement.
authors.affiliation: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Hubei Province, China. hua.j@hotmail.com
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
authors.forename: Chang-Sheng
authors.initials: CS
authors.lastname: Deng
authors.forename: Ming
authors.initials: M
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Xia
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002908:Chronic Disease; D003092:Colitis / Q000139:chemically induced* / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003106:Colon / Q000737:chemistry / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D003474:Curcumin / Q000494:pharmacology / Q000627:therapeutic use*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015232:Dinoprostone / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000502:physiology; D007371:Interferon-gamma / Q000032:analysis / Q000235:genetics / Q000502:physiology; D007413:Intestinal Mucosa / Q000737:chemistry / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D007962:Leukocytes / Q000473:pathology / Q000502:physiology; D052247:Nitric Oxide Synthase Type II / Q000032:analysis / Q000235:genetics / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014302:Trinitrobenzenesulfonic Acid / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000235:genetics / Q000502:physiology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D051546:Cyclooxygenase 2; D003474:Curcumin; D015232:Dinoprostone